Affiliation:
1. Baskent University Faculty of Medicine, Department of Pulmonary Diseases
2. Baskent University Faculty of Medicine, Department of Internal Medicine
3. Baskent University Faculty of Medicine, Department of Infectious Diseases
4. Baskent University Faculty of Medicine, Department of Radiology
5. Baskent University, Department of Biostatistics
Abstract
OBJECTIVE: Influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are agents that spread through droplets, have similar symptoms and radiological findings, and can cause respiratory failure. This study was conducted to compare the clinical features and mortality rates of patients with novel coronavirus disease (COVID-19), influenza, and respiratory syncytial virus pneumonia.
MATERIAL AND METHODS: A total of 182 patients who were hospitalized at Baskent University Medical Faculty Hospital due to COVID-19, influenza, and RSV were included in the study. Patients were grouped according to their clinical status. Demographic characteristics, comorbidities, laboratory and radiological findings, respiratory support treatments and mortality rates of the patients were recorded and compared between the groups.
RESULTS: The mean age was 69.4±7 years in the COVID-19 group (n:115), 72.9±17.1 years in the influenza group (n:33), and 66.5±22.4 years in the RSV group (n:34). There was no difference in age between the groups (p=0.305). The hospitalization rate was higher for male patients in the COVID-19 group (p=0.036). There was no difference between the groups in terms of comorbidities (p>0.05). There was no difference in mortality rates between the COVID-19, RSV, and influenza patient groups (p=0.260).
CONCLUSIONS: Viral infections with pulmonary involvement require special attention because they can have a poor clinical course. The severity of the clinical course of COVID-19 pneumonia, which causes deaths in the current century, is not different from the clinical course of viral infections such as influenza and RSV.
Funder
Bu çalışma Başkent Üniversitesi Araştırma Fonu tarafınca desteklenmiştir.
Publisher
Afyon Kocatepe University
Reference26 articles.
1. 1. Cavallazzi R. Ramirez JA. Influenza and viral pneumonia. Clin Chest Med. 2018;39(4):703-21.
2. 2. Kim HJ, Choi SM, Lee J, et al. Respiratory virus of severe pneumonia in South Korea: Prevalence and clinical implications. PLoS One. 2018;13(6):e0198902.
3. 3. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: A systematic literature review. Adv Clin Exp Med. 2021;30(1):109-14.
4. 4. T.C. Ministry of Health, General Directorate of Public Health, COVID-19 (SARS-CoV-2 Infection) Adult Patient Treatment. April 12, 2022, Ankara. Available from:
https://covid19.saglik.gov.tr/Eklenti/43095/0/covid19rehberieriskinhastayonetimivetedavi-12042022pdf, Accessed date:08.03.2023.
5. 5. Auvinen R, Nohynek H, Syrjänen R, et al. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients-a prospective observational study. Infect Dis (Lond).
2021;53(2):111-21.